MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer

Peking University484 enrolled

Overview

This is a prospective, multicenter, non-interventional, controlled clinical study. Evaluate MDT performance and benefit analysis in patients with advanced gastric or colorectal cancer after MDT discussion under real medical practice.

Study Type

OBSERVATIONAL

Enrollment

484

Conditions

Multi-disciplinary Treatment

Interventions

Multi-disciplinary TreatmentPROCEDURE

due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Histopathological diagnosis of recurrent / metastatic gastric or colorectal cancer. 2. Participate in formal MDT discussions at the Research Center. 3. MDT decision-making at least two subjects involved in treatment. 4. Patient informed consent and signed written consent. Exclusion Criteria: 1. Early or locally advanced gastric cancer or colorectal cancer. 2. Accept informal MDT discussions. 3. MDT decisions recommend only a single subject for treatment of patients. 4. MDT decisions recommend only palliative patients.

Locations (1)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

overall survival

From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Secondary Outcomes

Differences in overall survival after performing MDT at center

Time frame: 1 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.